ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
about
H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signalingModeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expressionIn vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin BAn extra copy of p53 suppresses development of spontaneous Kras-driven but not radiation-induced cancerSomatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.Combination of celecoxib and PD184161 exerts synergistic inhibitory effects on gallbladder cancer cell proliferation.High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)Protein signature for non-small cell lung cancer prognosis.A network-based biomarker approach for molecular investigation and diagnosis of lung cancer.The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinomaInhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination.Selective activation of p53-mediated tumour suppression in high-grade tumours.Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppressionRegulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells.Molecular mechanisms of cigarette smoke-induced proliferation of lung cells and prevention by vitamin C.Molecular characterization of the peripheral airway field of cancerization in lung adenocarcinoma.Epidermal growth factor receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear trafficking.Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor.A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.Isolation of intrinsically active (MEK-independent) variants of the ERK family of mitogen-activated protein (MAP) kinasesDifferentially expressed and activated proteins associated with non small cell lung cancer tissuesHigh PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinomaERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics.Targeting the mitogen-activated protein kinase cascade to treat cancer.Atomic force microscopy characterization of kinase-mediated phosphorylation of a peptide monolayer.Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance.Early and delayed intervention with rapamycin prevents NNK-induced lung adenocarcinoma in A/J mice.Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC).Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cellsMutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilitiesCold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers.APRIL, BCMA and TACI proteins are abnormally expressed in non-small cell lung cancer.A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis.Targeting EP4 downstream c-Jun through ERK1/2-mediated reduction of DNMT1 reveals novel mechanism of solamargine-inhibited growth of lung cancer cellsΔNp63α regulates Erk signaling via MKP3 to inhibit cancer metastasis.Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.ERK and AKT phosphorylation status in lung cancer and emphysema using nanocapillary isoelectric focusing.C-Raf is required for the initiation of lung cancer by K-Ras(G12D).
P2860
Q24671049-96096C38-FAE7-4A3F-B611-E8F156C32DC0Q28484612-20B753F9-AF1C-42EB-96B3-9F304C2DE5EFQ28543407-ECAFDEBC-5442-4004-80B5-E85874F4FB57Q28596032-5454EFD1-79E9-4F88-9EAA-D3603E5B8E5DQ33671646-87A4C0B8-7444-4F6C-8AF9-909B3BE6FEFCQ33684263-3D9C2940-4466-4666-84CE-2A53BFFD3406Q33717222-1DC2C2B6-24DC-4EE9-82BF-8BBF933A2092Q33785608-7943B315-8006-4E26-AC2F-E9715CE66316Q33787452-B5438A6E-AE8C-4724-B65F-29AE502BFEE8Q33995206-2317C656-651F-49DE-825B-9D1324AFD7C3Q34094986-C7F6626C-6CD8-4951-A160-A9A91D47C0B5Q34151826-DF9BCA10-C53C-44A5-B0D8-E6FB1EE8D17EQ34648711-87647B80-2288-42C1-AE85-32DBFC3624B7Q34881610-C3CEF199-D6BD-4764-ACAB-EFD09F7F47B1Q35104755-DF6D158A-454A-4050-9DFF-A406BE95EAFFQ35113376-52D08E67-7592-446C-A751-34C96BF8778CQ35207808-316437C7-B234-4105-8C16-73679D0DD35AQ35207885-8268A881-BF6C-4920-BC28-C610B11CA281Q35221788-EA2B2AEA-676B-41DD-B83C-4495363F0739Q35649378-07FE18C4-49AB-4C21-880E-CA92C5C79552Q35676869-FD01D647-270D-4DE8-B826-3EFA5D1E2D00Q35805319-22BC57F8-47D3-49E9-AFC4-574AEC4CC2CCQ35805551-3CE777AD-E64B-4B43-93C0-F243242DA244Q35873526-CB4DDEFA-31CC-438B-B828-438F02693918Q35968411-CB813256-A9C8-4006-BD89-ADAE1669CDC4Q36191446-C35F2C2E-588D-4F46-B283-89F35AB3298AQ36511724-54EA7384-B68B-4114-B451-C7858EE11350Q36528118-7771557A-8568-4593-8B2B-228B144F4CCDQ36640209-374731AF-7121-4DC0-AC75-3A3F31C7E39BQ36643420-1004036A-BEB9-4002-8F83-ED871C338EBBQ36657702-4909AB43-DC9D-4C92-AE70-CCB39C0B47A2Q36962542-B6C2CEBC-96D7-4642-A2C8-E0B8BE31A5E0Q37023660-7A5B37B1-0E25-4936-8ED3-F5E1A5136B81Q37406949-16051A4D-BA9F-4CE7-836D-01FF0B57F512Q37573669-C486954F-6461-4AEA-9CF6-0A41A26448B2Q37604381-D7E01E79-BFFD-4822-BAF3-981FD3915C3EQ37656142-B4A1B234-2BEB-4B6A-A7ED-34CF47D1EE42Q37667783-F2B14CFF-55A1-439F-B3ED-6CF009EBAC9DQ38583728-DCB65F5B-CD68-4818-A7FB-E04B1D65F8E0Q38854172-55A467C9-02CD-449C-B5C5-685CA2B38D40
P2860
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
@ast
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
@en
type
label
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
@ast
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
@en
prefLabel
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
@ast
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.
@en
P2093
P2860
P356
P1476
ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours
@en
P2093
C Garcia-Corchón
L M Montuenga
M D Lozano
R G Manzano
S Martín-Algarra
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601644
P407
P577
2004-03-01T00:00:00Z